Terms: = Brain cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
104 results:
1. Design, synthesis and anticancer evaluation of novel arylhydrazones of active methylene compounds.
Murugesan A; Konda Mani S; Koochakkhani S; Subramanian K; Kandhavelu J; Thiyagarajan R; Gurbanov AV; Mahmudov KT; Kandhavelu M
Int J Biol Macromol; 2024 Jan; 254(Pt 3):127909. PubMed ID: 37951450
[TBL] [Abstract] [Full Text] [Related]
2. Recent advances in the discovery of tropomyosin receptor kinases trks inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract] [Full Text] [Related]
3. Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer.
Wolff L; Steindl A; Popov P; Dieckmann K; Gatterbauer B; Widhalm G; Berghoff AS; Preusser M; Raderer M; Kiesewetter B
Clin Exp Metastasis; 2023 Jun; 40(3):217-226. PubMed ID: 37219741
[TBL] [Abstract] [Full Text] [Related]
4. Head-to-Head Comparison of [
Ballal S; Yadav MP; Roesch F; Raju S; Satapathy S; Sheokand P; Moon ES; Martin M; Awarwal S; Tripathi M; Bal C
Thyroid; 2023 Aug; 33(8):974-982. PubMed ID: 37171126
[No Abstract] [Full Text] [Related]
5. LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
Hardin EC; Schmid S; Sommerkamp A; Bodden C; Heipertz AE; Sievers P; Wittmann A; Milde T; Pfister SM; von Deimling A; Horn S; Herz NA; Simon M; Perera AA; Azizi A; Cruz O; Curry S; Van Damme A; Garami M; Hargrave D; Kattamis A; Kotnik BF; Lähteenmäki P; Scheinemann K; Schouten-van Meeteren AYN; Sehested A; Viscardi E; Wormdal OM; Zapotocky M; Ziegler DS; Koch A; Hernáiz Driever P; Witt O; Capper D; Sahm F; Jones DTW; van Tilburg CM
Neuro Oncol; 2023 Nov; 25(11):2087-2097. PubMed ID: 37075810
[TBL] [Abstract] [Full Text] [Related]
6. Characterization of LTr1 derived from cruciferous vegetables as a novel anti-glioma agent via inhibiting trka/PI3K/AKT pathway.
Song QQ; Lin LP; Chen YL; Qian JC; Wei K; Su JW; Ding JH; Lu M; Liu Y; Tan RX; Hu G
Acta Pharmacol Sin; 2023 Jun; 44(6):1262-1276. PubMed ID: 36482085
[TBL] [Abstract] [Full Text] [Related]
7. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
Schirrmacher V; van Gool S; Stuecker W
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361831
[TBL] [Abstract] [Full Text] [Related]
8. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract] [Full Text] [Related]
9. Rationale and design of ON-trk: a novel prospective non-interventional study in patients with trk fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract] [Full Text] [Related]
10. brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of ntrk1-rearranged tumor cells.
Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
[TBL] [Abstract] [Full Text] [Related]
12. trka-cholinergic signaling modulates fear encoding and extinction learning in PTSD-like behavior.
Yanpallewar S; Tomassoni-Ardori F; Palko ME; Hong Z; Kiris E; Becker J; Fulgenzi G; Tessarollo L
Transl Psychiatry; 2022 Mar; 12(1):111. PubMed ID: 35301275
[TBL] [Abstract] [Full Text] [Related]
13. Related expression of trka and P75 receptors and the changing copy number of
Chernov AN; Alaverdian DA; Glotov OS; Talabaev MV; Urazov SP; Shcherbak SG; Renieri A; Frullanti E; Shamova O
Drug Metab Pers Ther; 2020 Sep; 35(4):. PubMed ID: 34704697
[TBL] [Abstract] [Full Text] [Related]
14. Detection of Ntrk fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-trk immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract] [Full Text] [Related]
15. hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF.
Franzese O; Di Francesco AM; Meco D; Graziani G; Cusano G; Levati L; Riccardi R; Ruggiero A
Pathol Oncol Res; 2021; 27():612375. PubMed ID: 34257579
[TBL] [Abstract] [Full Text] [Related]
16. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of a rare
Deland L; Keane S; Olsson Bontell T; Sjögren H; Fagman H; Øra I; De La Cuesta E; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Biol Ther; 2021 Mar; 22(3):184-195. PubMed ID: 33820494
[TBL] [Abstract] [Full Text] [Related]
18. ABCB1 and ABCG2 Restrict brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel trk Inhibitor Selitrectinib.
Li W; Sparidans RW; Martins MLF; El-Lari M; Lebre MC; van Tellingen O; Beijnen JH; Schinkel AH
Mol Cancer Ther; 2021 Jun; 20(6):1173-1182. PubMed ID: 33785654
[TBL] [Abstract] [Full Text] [Related]
19. Ntrk Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.
Dahl NA; Donson AM; Sanford B; Wang D; Walker FM; Gilani A; Foreman NK; Tinkle CL; Baker SJ; Hoffman LM; Venkataraman S; Vibhakar R
J Neuropathol Exp Neurol; 2021 Mar; 80(4):345-353. PubMed ID: 33749791
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (trk) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract] [Full Text] [Related]
[Next]
